Although the results of these clinical trials do not appear to be particularly encouraging, in a recent BAMM (BRAF Autophagy and MEK Inhibition in Melanoma) trial (NCT02257424), a four-center, phase I/II trial of dabrafenib, trametinib, and HCQ in BRAF inhibitor-naïve patients with advanced BRAF mutant melanoma, HCQ + dabrafenib+trametinib was well tolerated and produced a high response rate (RR) but did not meet criteria for success for the one-year progression-free survival (PFS) rate. The gene discussed is MAP2K7; the disease is melanoma.